Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Open Doors is an annual celebration of Oxford’s unique buildings and spaces run by the Oxford Preservation Trust as part of the Heritage open days scheme. This year, over 100 buildings are taking part in the event that runs from the 8-9th September, including several Medical Sciences Departments.

Medical Sciences at Oxford Open Doors

On Saturday 8 September, facilities at the Old Road Campus, including the Richard Doll building (housing the Nuffield Department of Population Health) and the Old Road Campus Research Building (ORCRB, housing Oncology and the Nuffield Department of Medicine units Ludwig Cancer Research, the Jenner Institute and the Structural Genomics Consortium) will be opening their doors to the public. Visitors will have the chance to learn about the medical research behind the headlines via fun family-friendly science fair activities, talks by leading academics, and tours of real scientific laboratories. In the Richard Doll building (10 am – 4 pm), topics will include statins, Million Women Study, clinical trials, diet and exercise, breastfeeding, antibiotics, cancer, heart disease and stroke.

Oxford Open Doors2.jpg

Activities for the day

In the ORCRB (12.30 - 3pm), visitors will explore the transmission of infectious diseases such as malaria by building a model mosquito, learn about 3D packing in protein crystals using jelly babies, understand the use of medical imaging techniques with a guess-the-fruit activity and discover the effect of DNA mutations by translating coded messages and a microscope demonstration of fluorescent fish.

The Sir William Dunn School of Pathology on Parks Road will also be opening its doors to the public, offering tours of the building and its facilities, and a talk focusing on the history of penicillin and pathology.

Oxford Open Doors logo.png

Similar stories

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.